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Prevention of neonatal pneumonia and sepsis via maternal 
immunisation
Pneumonia is the leading killer of children younger 
than 5 years, and the greatest risk of mortality from 
pneumonia in childhood is in the neonatal period.1 
Substantial reductions in childhood pneumonia deaths 
have been hindered by a lack of progress in addressing 
neonatal mortality. Deaths in the neonatal period 
constitute 41·6% of the 6·3 million children who die 
annually before their ﬁ fth birthday.2 In 2010, there were 
an estimated 1·7 million cases of neonatal sepsis and 
510 000 cases of neonatal pneumonia.3 On Nov 12, World 
Pneumonia Day, we focus on prevention of pneumonia in 
these youngest and most susceptible victims.
Early-onset neonatal pneumonia is mostly acquired 
from the mother during labour or delivery, and 
commonly presents with respiratory distress beginning 
at, or soon after, birth. Because signs of pneumonia 
are non-speciﬁ c in neonates, any newborn infant with 
sudden onset of respiratory distress or other signs of 
illness should be assessed for pneumonia and sepsis. 
Successful treatment depends on the pathogen, early 
recognition of the infection, and prompt therapy before 
the development of irreversible injury. In resource-
limited settings, however, timely diagnosis and treat-
ment is often not possible and mortality is high.
Eﬀ orts to prevent neonatal pneumonia and sepsis 
have been few, despite being essential for reduction of 
this high mortality. Active immunisation is not always 
possible in neonates because of the immaturity of 
the neonatal immune system and the several weeks 
necessary for protective immunity to develop. Beyond 
herd protection of neonates through immunisation 
of older children with Streptococcus pneumoniae and 
Haemophilus inﬂ uenzae type b (Hib) conjugate vaccines, 
existing vaccine interventions during infancy have so far 
not substantially reduced neonatal mortality. Maternal 
immunisation is a viable approach for protection of 
young infants from the most common infectious causes 
of mortality, both by allowing suﬃ  cient protection 
through the passive placental transfer of maternal 
antibodies to the fetus and by enabling reduced mother-
to-child transmission of infection. Safe and eﬀ ective, 
maternal antenatal immunisation allows the neonate 
to acquire necessary pathogen-speciﬁ c antibody 
concentrations to ﬁ ght infections during a discrete but 
heightened period of susceptibility.4 
For example, through sustained emphasis on 
improvement of vaccination coverage, the Maternal 
and Neonatal Tetanus Elimination Initiative has made 
substantial progress in the elimination of maternal 
and neonatal tetanus.5 The H1N1 inﬂ uenza pandemic 
in 2009 prompted new recommendations for routine 
maternal immunisation against inﬂ uenza and 
pertussis in pregnant women in the USA and UK.6 In 
response to an outbreak across England, a pertussis 
vaccination programme for pregnant women was 
introduced in 2012. It has been shown to have high 
vaccine eﬀ ectiveness among infants.7 In a small trial 
from Bangladesh, inﬂ uenza vaccination of mothers in 
addition to pneumococcal conjugate or Hib vaccination 
of their infants was eﬀ ective against respiratory illness 
during early infancy.8 Furthermore, maternal inﬂ uenza 
immunisation in a 2014 South African trial showed 
vaccine eﬃ  cacy both among mothers infected with HIV 
and among uninfected mothers, and protection of HIV-
uninfected infants.9 Currently, inﬂ uenza trials in Mali, 
Nepal, and South Africa are studying a wide range of 
beneﬁ ts to the mother, fetus, and for the ﬁ rst 6 months 
of life, the neonate. 
The opportunity to increase the coverage of inﬂ uenza 
and pertussis immunisation in pregnant women 
in developing countries is substantial, but several 
challenges are clear. WHO recommends maternal 
pertussis vaccination as the most cost-eﬀ ective strategy 
for reduction of neonatal pertussis mortality in high-
burden countries, but obstacles remain. These include 
diagnostic challenges, under-reporting, and a paucity of 
data on incidence of neonatal pertussis.10 Furthermore, 
the acellular pertussis vaccines available at present are 
expensive. Development of an eﬀ ective low-cost vaccine 
is essential for adoption in low-income countries.
There is also scope to develop new maternal vaccines 
to protect infants. Group B streptococci (GBS) and 
respiratory syncytial virus (RSV) infections are serious 
and frequent causes of neonatal morbidity and 
mortality, and oﬀ er important potential opportunities 
for maternal immunisation.11 One in four women 
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carry GBS vaginally.12 At increased risk of infection 
and mortality, up to 3% of infants with very low 
birthweights become infected, with mortality rates of 
up to 30%, even with immediate antibiotic treatment. 
Maternal GBS vaccination would be cost-eﬀ ective.13,14 
The safety and immunogenicity of a maternal GBS 
candidate vaccine is under evaluation. First lifetime 
RSV infections are responsible for up to 22% of severe 
lower respiratory tract infections in children younger 
than 5 years. They occur at a very early age, in a seasonal 
pattern, and lead to bacterial coinfections in about a 
third of patients.15 GBS and RSV vaccines are crucial 
to reduction of neonatal mortality, and maternal 
immunisation shows potential to achieve improved 
protection of the neonate.
As shown by tetanus, inﬂ uenza, and pertussis 
vaccination during pregnancy, maternal immunisation 
is a safe and eﬀ ective approach for prevention of 
infection in neonates, and could be a promising strategy 
to address neonatal pneumonia and sepsis. 
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